Sara Bouberhan

762 total citations
26 papers, 281 citations indexed

About

Sara Bouberhan is a scholar working on Oncology, Reproductive Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Sara Bouberhan has authored 26 papers receiving a total of 281 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Reproductive Medicine and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Sara Bouberhan's work include Ovarian cancer diagnosis and treatment (11 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Advanced Breast Cancer Therapies (5 papers). Sara Bouberhan is often cited by papers focused on Ovarian cancer diagnosis and treatment (11 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Advanced Breast Cancer Therapies (5 papers). Sara Bouberhan collaborates with scholars based in United States, Belgium and Australia. Sara Bouberhan's co-authors include Meghan Shea, Michele R. Hacker, Katharine M. Esselen, Stephen A. Cannistra, Éric Pujade-Lauraine, Mary K. Buss, Maria Pisu, Warner K. Huh, Margaret Liang and Annika Gompers and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Sara Bouberhan

22 papers receiving 278 citations

Peers

Countries citing papers authored by Sara Bouberhan

Since Specialization

Citations

This map shows the geographic impact of Sara Bouberhan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Bouberhan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Bouberhan more than expected).

Fields of papers citing papers by Sara Bouberhan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Bouberhan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Bouberhan. The network helps show where Sara Bouberhan may publish in the future.

Co-authorship network of co-authors of Sara Bouberhan

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Bouberhan. A scholar is included among the top collaborators of Sara Bouberhan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Bouberhan. Sara Bouberhan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer 2025 ·JCO Precision Oncology ·Panagiotis A. Konstantinopoulos, (unknown), Elizabeth K. Lee, Carolyn Krasner, Susana M. Campos, Joyce F. Liu, Neil S. Horowitz, Meghan Shea, Heather A. Parsons, Alexi A. Wright, Sara Bouberhan, Richard T. Penson, Oladapo Yeku, (unknown), (unknown), Madeline Polak, Cesar M. Castro, Su–Chun Cheng, Caroline Weipert, Ursula A. Matulonis	0
2	Phase 2 study of letrozole, abemaciclib, and metformin in estrogen receptor (ER)–positive recurrent endometrial cancer (EC). 2025 ·Journal of Clinical Oncology ·Panagiotis A. Konstantinopoulos, (unknown), Richard T. Penson, Susana M. Campos, Carolyn Krasner, Alexi A. Wright, Rebecca L. Porter, Neil S. Horowitz, Sara Bouberhan, (unknown), (unknown), (unknown), Madeline Polak, Meghan Shea, Page Widick, Su–Chun Cheng, Cesar M. Castro, Ursula A. Matulonis, (unknown)	1
3	A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer. 2024 ·Journal of Clinical Oncology ·(unknown), Sara Bouberhan, Konstantinos Papadimitriou, Rebecca C. Arend, (unknown), Roisin E. O’Cearbhaill, David M. O’Malley, Benoît You, Antonio González-Martı́n, Judith Michels, Linda Mileshkin, Yeh Chen Lee, (unknown), Suk‐Young Yoo, (unknown), (unknown), David A. Knorr, Israel Lowy, Thomas S. Uldrick, Elizabeth Miller	7
4	A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer: Trial in progress update 2024 ·Gynecologic Oncology ·Joyce F. Liu, David M. O’Malley, (unknown), Roisin E. O’Cearbhaill, Sara Bouberhan, Kathleen N. Moore, June Y. Hou, Erika Hamilton, Suk‐Young Yoo, Bin Wang, (unknown), (unknown), David A. Knorr, Israel Lowy, Thomas S. Uldrick, Elizabeth Miller	1
5	Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole/abemaciclib in endometrial cancer (EC). 2024 ·Journal of Clinical Oncology ·Panagiotis A. Konstantinopoulos, Mingyang Cai, (unknown), Niya Xiong, Carolyn Krasner, Susana M. Campos, Joyce F. Liu, Neil S. Horowitz, Alexi A. Wright, Meghan Shea, Sara Bouberhan, Richard T. Penson, Oladapo Yeku, (unknown), (unknown), Madeline Polak, Cesar M. Castro, Su–Chun Cheng, Caroline Weipert, Ursula A. Matulonis	0
6	PO001/#1130 Impact of investigator-assessed response to dostarlimab on quality of life in the ruby trial of primary advanced or recurrent endometrial cancer (PA/REC) 2024 ·Noelle Cloven, Henrik Roed, Lucy Gilbert, Zoltán Novàk, Mitchell I. Edelson, Antonella Savarese, Kari L. Ring, Martina Gropp‐Meier, (unknown), (unknown), Sara Bouberhan, Floor Backes, Robert Coleman, (unknown), Alberto A. Mendivil, Solomon J. Lubinga, (unknown), Kateryna Chepynoga, Matthew A. Powell, (unknown)	1
7	Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors 2023 ·JNCI Journal of the National Cancer Institute ·Shruti Gupta, (unknown), (unknown), Sofía Martínez, (unknown), Qiyu Wang, (unknown), (unknown), Carolyn Krasner, Sara Bouberhan, Cesar M. Castro, Meghan E. Sise	8
8	TP020/#1513 First-in-human phase 1/2 study of ubamatamab, a MUC16XCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer 2023 ·Lirias (KU Leuven) ·Kathleen N. Moore, Sara Bouberhan, Erika Hamilton, Joyce Liu, Roisin E. O’Cearbhaill, David M. O’Malley, Konstantinos Papadimitriou, (unknown), Els Van Nieuwenhuysen, Suk‐Young Yoo, Bin Wang, (unknown), Priscila Gonçalves, (unknown), Min Zhu, Israel Lowy, Thomas S. Uldrick, Elizabeth Miller	3
9	Mechanisms of resistance to bispecific T-cell engager therapy for ovarian cancer. 2023 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Yusuke Matoba, (unknown), Eugene Kim, Amy Bregar, Eric Eisenhauer, Richard T. Penson, Sara Bouberhan, (unknown), (unknown), Cesar M. Castro, David R. Spriggs, Bo R. Rueda, Oladapo Yeku	1
10	The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer 2023 ·Cancer Drug Resistance ·Sara Bouberhan, Liron Bar‐Peled, Yusuke Matoba, (unknown), (unknown), Bo R. Rueda	7
11	A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC). 2023 ·Journal of Clinical Oncology ·(unknown), Niya Xiong, Su–Chun Cheng, Madeline Polak, Carolyn Krasner, Susana M. Campos, Alexi A. Wright, Joyce F. Liu, Meghan Shea, Oladapo Yeku, Cesar M. Castro, Rebecca L. Porter, Elizabeth H. Stover, Sara Bouberhan, John W. Moroney, Richard T. Penson, Gini F. Fleming, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos	1
12	127P REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study 2023 ·Immuno-Oncology Technology ·Ira Winer, Roisin E. O’Cearbhaill, Sara Bouberhan, John L. Hays, Robert M. Wenham, Dario R. Roque, Oladapo Yeku, (unknown), Bo Wang, (unknown), (unknown), Min Zhu, Jurriaan Brouwer‐Visser, (unknown), Benjamin A. Barnes, Israel Lowy, David A. Knorr, Thomas S. Uldrick, (unknown)	2
13	PO011LBA/#1512 Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (Anti-PD-1 antibody) in recurrent ovarian cancer: phase 1 clinical and biomarker results 2023 ·Lirias (KU Leuven) ·Joyce F. Liu, David M. O’Malley, Els Van Nieuwenhuysen, Kathleen N. Moore, Erika Hamilton, Oladapo Yeku, Sara Bouberhan, June Y. Hou, (unknown), Bin Wang, Suk‐Young Yoo, (unknown), Jurriaan Brouwer‐Visser, (unknown), (unknown), (unknown), Israel Lowy, Thomas S. Uldrick, Elizabeth Miller, Roisin E. O’Cearbhaill	2
14	Evaluating meaningful levels of financial toxicity in gynecologic cancers 2021 ·International Journal of Gynecological Cancer ·Katharine M. Esselen, Annika Gompers, Michele R. Hacker, Sara Bouberhan, Meghan Shea, (unknown), (unknown), Warner K. Huh, Maria Pisu, Margaret Liang	66
15	Incidence of immune related adverse events in patients with gynecologic cancers: a multi-institutional 20-year retrospective review 2021 ·Gynecologic Oncology ·(unknown), (unknown), Cesar M. Castro, Amy Bregar, Joyce F. Liu, Richard T. Penson, Sara Bouberhan, David R. Spriggs, Oladapo Yeku	2
16	LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer 2020 ·Annals of Oncology ·(unknown), (unknown), Niya Xiong, Nabihah Tayob, Carolyn Krasner, Mary K. Buss, Susana M. Campos, Susan Schumer, Alexi A. Wright, (unknown), Meghan Shea, (unknown), Cesar M. Castro, Madeline Polak, C. Whalen, Sara Bouberhan, S A Cannistra, Richard T. Penson, Gini F. Fleming, Ursula A. Matulonis	11
17	Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer 2020 ·Cancers ·Sara Bouberhan, (unknown), Sarah J. Hill, Linah Al-Alem, Bo R. Rueda	7
18	Financial toxicity in gynecologic oncology 2019 ·Gynecologic Oncology ·Sara Bouberhan, Meghan Shea, Alice Kennedy, (unknown), (unknown), Mary K. Buss, (unknown), Kathleen F. Nolan, Christopher S. Awtrey, John L. Dalrymple, Leslie A. Garrett, (unknown), Michele R. Hacker, Katharine M. Esselen	89
19	Polymyositis as a presentation of advanced carcinoma of Mullerian origin: A case report and discussion 2018 ·Gynecologic Oncology Reports ·(unknown), Sara Bouberhan, Elizabeth M. Raynor, Meghan Shea, Fong Liu	2
20	Patient preferences regarding incidental genomic findings discovered during tumor profiling 2016 ·Cancer ·Melinda Yushak, Gang Han, Sara Bouberhan, (unknown), Michael P. DiGiovanna, Sarah S. Mougalian, Tara Sanft, Maysa Abu‐Khalaf, Gina G. Chung, Stacey Stein, Sarah B. Goldberg, Lajos Pusztai, Erin Hofstatter	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact